RedHill Biopharma

Company Overview

Snapshot

Founded in August 2009 by Dror Ben-Asher, RedHill Biopharma operates with 11–50 employees. The company has raised a total of $307.15 million across 23 funding rounds from 14 investors. In October 2025, RedHill's Talicia secured a $4 million strategic investment and a U.S. co-commercialization partnership deal with Cumberland Pharmaceuticals.

Business overview

RedHill Biopharma is a specialty biopharmaceutical company focused on developing and commercializing proprietary drugs for gastrointestinal and infectious diseases. The company's portfolio includes two FDA-approved drugs, Talicia and Aemcolo, which are promoted in the U.S. by a dedicated sales team. RedHill also maintains an advanced, late-stage clinical development pipeline addressing significant unmet medical needs in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In October 2025, RedHill Biopharma secured a $4 million strategic investment and a U.S. co-commercialization partnership for its drug Talicia with Cumberland Pharmaceuticals. This partnership, which includes Cumberland Pharmaceuticals taking a 30% ownership stake and joint control in RedHill's Talicia business, signals strong market validation and a strategic move to accelerate commercialization and expand market reach for a key product.

Company Intelligence Q&A

What was the outcome of the New York Supreme Court appeal for RedHill Biopharma?

In September 2025, the New York Supreme Court upheld its original summary judgment ruling in favor of RedHill Biopharma, dismissing an appeal and affirming a $10 million summary judgment against Kukbo.

What strategic deal did RedHill Biopharma sign in the Middle East for Talicia?

In October 2025, RedHill Biopharma signed a new $1.8 million deal, plus sales royalties, for Talicia in the Middle East. This agreement aims to accelerate Talicia's entry into new markets in the region.

What was the recent development regarding RedHill Biopharma's compliance with Nasdaq listing requirements?

In October 2025, RedHill Biopharma received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with listing requirements.

What was the outcome of the collaboration between RedHill Biopharma and Cumberland Pharmaceuticals?

In October 2025, RedHill's Talicia secured a $4 million strategic investment and a U.S. co-commercialization partnership deal with Cumberland Pharmaceuticals, which invested $4 million for a 30% ownership stake and joint control in RedHill's Talicia business.

What was the status of RedHill Biopharma's Opaganib in relation to COVID-19 mortality data?

In September 2024, a new peer-reviewed publication of Opaganib Phase 2/3 data showed a 62% reduction in COVID-19 mortality.